@article{f8d9009de9d04f9aa7481d6409faf144,
title = "Interruption of natalizumab therapy for multiple sclerosis: What are the risks?",
author = "Naismith, {Robert T.} and Dennis Bourdette",
note = "Funding Information: Dr. Naismith has received travel expenses and/or honoraria for lectures, educational activities, and consulting from Acorda Therapeutics Inc., Bayer Schering Pharma, Biogen Idec, EMD Serono, Inc., Genzyme Corporation, and Teva Pharmaceutical Industries Ltd.; serves as an Associate Editor for Journal Watch ; serves on speakers' bureaus for Acorda Therapeutics Inc., Bayer Schering Pharma, Biogen Idec, EMD Serono, Inc., and Teva Pharmaceutical Industries Ltd.; and receives research support from Acorda Therapeutics Inc. and the NIH. Dr. Bourdette has received travel expenses and/or honoraria for lectures and educational activities from Teva Pharmaceutical Industries Ltd., Biogen Idec, and EMD Serono, Inc.; serves as an Associate Editor for Journal of Medicinal Medicine and Autoimmune Diseases and as Section Editor for Current Neurology and Neuroscience Reports ; and has research support from the US Department of Veterans Affairs, the NIH, and the National Multiple Sclerosis Society.",
year = "2011",
month = may,
day = "31",
doi = "10.1212/WNL.0b013e31821d7553",
language = "English",
volume = "76",
pages = "1854--1855",
journal = "Neurology",
issn = "0028-3878",
number = "22",
}